We have had 3 amazing people join the Sable team all of whom are starting to help us form and shape our product and data strategies.
Prior to joining Sable, Clare led the development of AI-enabled target identification products at BenevolentAI, translating biological data into actionable insights for drug discovery scientists. Clare holds a DPhil in Protein Informatics from the University of Oxford and has held research positions at the Centre for Medicines Discovery, University of Oxford, and Open Targets.
<aside> 🧬 In addition to shaping our product strategy, Clare will be focussed on building methods that harness biological datasets, such as genetics, to predict and contextualise potential safety and toxicity risks.
</aside>
Prior to joining Sable, Olly spent eight years at BenevolentAI working on applications, data pipelines and Natural Language Processing (NLP) techniques, as VP of Product Engineering. Olly previously worked in Engineering and User Experience for UK media organisations including the Telegraph and the Guardian. He holds a PhD in Computer Vision and Machine Learning.
<aside> 💡 Olly is focussing initially on detailing the product we’re building, in order to establish the right architecture and efficient ways for our scientists to contribute robust analyses.
</aside>
Prior to joining Sable, Camille worked in data science and machine learning roles within healthcare, spanning industry and academia, and holding positions at Imperial College London, Eli Lilly, IQVIA, and Parexel. He holds a medical degree with a specialisation in Public Health, as well as Master's degrees in Applied Mathematics and Public health from University Paris-Cité and University Paris-Saclay respectively.
<aside> 🩺 Alongside optimising our AI/ML strategy, Camille spearheads the development of our clinical pipeline by leveraging numerous real-world datasets.
</aside>
Had to ruin a perfectly good team call screenshot with a google hangouts pop-up!